Kristin A. Zabrecky

Kristin A. Zabrecky

Auto-generated profile, based on publicly available information

Kristin A. Zabrecky

Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2025 in Science
Verified
Journal Article
Closed access
RBRoss C. Bretherton
Ross C. Bretherton
IRIsabella M. Reichardt
Isabella M. Reichardt
KZKristin A. Zabrecky
Kristin A. Zabrecky
ANAbigail Nagle
Abigail Nagle
LBLogan R. J. Bailey
Logan R. J. Bailey
JDJennifer Davis
Jennifer Davis
Cardiomyocyte hypocontractility underlies inherited dilated cardiomyopathy (DCM). Yet, whether fibroblasts modify DCM phenotypes remains unclear despite their regulation of fibrosis, which strongly predicts disease severity. Expression of a hypocontractility-linked sarcomeric variant in mice triggered cardiac fibroblast expansion from the de novo formation of hyperproliferative mechanosensitized fibroblast states, which occurred prior to eccentric myocyte remodeling. Initially, this fibroblast response reorganized fibrillar collagen and stiffened the myocardium, albeit without depositing fibrotic tissue. These adaptations coincided with heightened matrix–integrin receptor interactions and diastolic tension sensation at focal adhesions within fibroblasts. Targeted p38 deletion arrested these cardiac fibroblast responses in DCM mice, which prevented cardiomyocyte remodeling and improved contractility. p38-mediated fibroblast responses were essential regulators of DCM severity, marking a potential cellular target for therapeutic intervention.